Continued Access to RXDX-105
NCT03784378
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
3
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Ovarian Cancer
RET Gene Mutation
BRAF Gene Mutation
Interventions
DRUG:
RXDX-105
Sponsor
Memorial Sloan Kettering Cancer Center